8:30 am Morning Coffee & Networking
Advancing the Delivery of Oncolytic Virotherapies – Intertumoral vs Intravenous Administration
9:00 am Intravenous Administration of an Oncolytic Vesicular Stomatitis Virus: Clinical Experience to Date
Synopsis
- Voyager V1 has been administered intravenously to over 100 cancer patients in clinical trials
- Compelling evidence of single agent activity after a single infusion will be presented
9:30 am Allogeneic Stem Cell-Based Platforms to Potentiate and Deliver Oncolytic Virus Therapies
Synopsis
- Shortcomings of unprotected oncolytic virus therapies
- Advantages of Calidi’s stem cell-based platforms for potentiation of oncolytic virotherapies – preclinical data
- Calidi’s clinical programs
10:00 am Clinical Trials of Oncolytic Virotherapy for Brain Tumors
Synopsis
- Define how OV’s change the tumor microenvironment
- Review current status of clinical trials in brain tumors
- Focus on future avenues of research
10:30 am Morning Break & Refreshments
Navigating the Landscape – Investment, Regulatory Guidelines & Partnering
11:30 am Panel Discussion: Navigating the Field of Oncolytic Virus Partnering & Licensing
Synopsis
Understand the Necessary Parameters for An Attractive Potential New Partner in The Field of Oncolytic Viruses with Examples from The Field
- What are the fundamental assets a biotech must have when approaching large pharma for a potential licensing agreement or acquisition proposition?
- Acquisition vs Licensing: Is there a preferential route for large pharma?
- Where will future innovation come from within the field of oncolytic viruses?
12:30 pm Lunch Break & Networking
Insights from Within the Clinic: Demonstrating the New Generation of Oncolytic Viruses
1:30 pm Clinical Update & Lessons Learned with Talimogene Laherparepvec in Solid Tumor Oncology
2:00 pm Viral Immunotherapies for Cancer
Synopsis
- Oncolytic viruses, or viral immunotherapy, represent a new pillar in the treatment of cancer
- Oncolytic viruses can be combined with other immunotherapies to treat cancer
- Oncolytic viruses can be tailored to fit multiple indications based on biology and stage of disease, including disease interception in the presurgical setting
2:30 pm Rationale Design of Phase 1 Trial Combining Oncolytic Virotherapy with CAR-T Cells
Synopsis
- CAR-T therapy of solid tumors is limited by tumor microenvironments that exclude and suppress T cells such as huCART-meso cells targeting mesothelin
- VCN-01, a PH20 hyaluronidase-armed Oncolytic Virus degrades tumor extracellular matrix, reprograms the tumor microenvironment, and draws T cells into tumor lesions
- We designed a combination trial NCT05057715 to establish the safety, feasibility, and preliminary efficacy of a combination of huCART-meso cells and VCN-01 in patients with pancreatic or ovarian cancer
3:00 pm Afternoon Break & Refreshments
3:30 pm Oncolytic Viral Immunotherapy For Hard-To-Treat Solid Tumors
Synopsis
- Introduction to oncolytic viral immunotherapy as a new approach to induce a specific immune response against the injected solid tumor and uninjected distant metastases
- Clinical and immunological data showing the effects of experimental treatment with CAN-2409 in combination with immune checkpoint inhibitors (ICI) in patients with stage III/IV NSCLC who had an inadequate response to ICI as well treatment with CAN-2409 in combination with nivolumab and first-line standard of care in patients with high-grade glioma
- Clinical and immunological data showing the effects of CAN-3110 in patients with recurrent high-grade glioma
4:00 pm Pepticrad: Oncolytic Immunotherapy Approach for Solid Tumors In Combination With Checkpoint Blockade
Synopsis
- PeptiCRAd is a rapidly adaptable and cost-effective therapeutic cancer vaccine platform targeting multiple tumor antigens simultaneously
- Systemic T-cell mediated antitumor efficacy is synergistic with checkpoint blockade therapy
- First-in-human Phase 1 clinical trial starting H2/2022.